Using daily rhythms to improve treatment for brain cancer
Circadian interventions against glioblastoma
['FUNDING_R01'] · WASHINGTON UNIVERSITY · NIH-11004669
This study is looking at the best times to give chemotherapy for glioblastoma, a type of brain cancer, by observing how brain activity changes throughout the day, with the hope of finding ways to make treatments like Temozolomide more effective for patients.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | WASHINGTON UNIVERSITY (nih funded) |
| Locations | 1 site (SAINT LOUIS, UNITED STATES) |
| Trial ID | NIH-11004669 on ClinicalTrials.gov |
What this research studies
This research investigates how the timing of chemotherapy can be optimized to enhance its effectiveness against glioblastoma, a type of brain cancer. By studying the daily rhythms of neuronal activity, the researchers aim to identify the best times to administer treatments like Temozolomide. They will use advanced mouse models that mimic human brain tumors to explore how these tumors respond to treatment based on the time of day. The goal is to discover new therapeutic strategies that could significantly improve patient outcomes.
Who could benefit from this research
Good fit: Ideal candidates for this research are children and young adults diagnosed with glioblastoma who may benefit from innovative treatment approaches.
Not a fit: Patients with other types of brain tumors or those who are not eligible for chemotherapy may not receive benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatment schedules for glioblastoma, potentially improving survival rates and quality of life for patients.
How similar studies have performed: While timed delivery of chemotherapy has shown success in other cancers, this approach in glioblastoma is novel and has not been extensively tested.
Where this research is happening
SAINT LOUIS, UNITED STATES
- WASHINGTON UNIVERSITY — SAINT LOUIS, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: HERZOG, ERIK — WASHINGTON UNIVERSITY
- Study coordinator: HERZOG, ERIK
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.